Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Nephrol ; 24(1): 147, 2023 05 26.
Artigo em Inglês | MEDLINE | ID: mdl-37237412

RESUMO

BACKGROUND: Dimercaptosuccinic acid (DMSA) therapy is a kind of chelation therapy for patients with Wilson 's disease (WD). While there have been reports of side effects associated with DMSA, the development of membranous nephropathy as a result of this therapy is uncommon. CASE PRESENTATION: We present a case of a 19-year-old male patient with Wilson's disease who experienced proteinuria while receiving long-term DMSA treatment. Further evaluation revealed abnormally low levels of serum ceruloplasmin and serum albumin, as well as a 24-hour urinary protein excretion of 4599.98 mg/24 h. A renal biopsy confirmed the presence of membranous nephropathy. After ruling out other potential causes, we determined that the patient's membranous nephropathy was likely caused by DMSA. Following treatment with glucocorticoids, there was a significant reduction in proteinuria. CONCLUSION: This case highlights the possibility of DMSA-induced membranous nephropathy and the importance of considering this diagnosis in patients receiving DMSA treatment. Given the widespread use of DMSA in the treatment of Wilson's disease, further research is needed to fully understand the potential role of this drug in the development of membranous nephropathy.


Assuntos
Glomerulonefrite Membranosa , Degeneração Hepatolenticular , Masculino , Humanos , Adulto Jovem , Adulto , Degeneração Hepatolenticular/complicações , Degeneração Hepatolenticular/tratamento farmacológico , Degeneração Hepatolenticular/diagnóstico , Succímero/uso terapêutico , Glomerulonefrite Membranosa/induzido quimicamente , Glomerulonefrite Membranosa/complicações , Glomerulonefrite Membranosa/diagnóstico , Cobre/metabolismo , Cobre/uso terapêutico , Proteinúria/induzido quimicamente , Proteinúria/complicações
2.
Exp Gerontol ; 46(8): 628-36, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21277365

RESUMO

Fuzhisan (FZS), a Chinese herbal complex prescription, has been used in the treatment of Alzheimer's disease (AD) for more than 16 years. However the underlying mechanism remains to be explored. The effects of the aqueous extract of FZS on the cognitive functions of the aged mice and the pharmacological basis for its therapeutic efficacy were investigated. The results showed that FZS improved impaired cognitive ability of aged SAMP-8 mice. FZS (2.4, 4.8 g/kg/d) increased hippocampal neurogenesis and the long-term survival of BrdU-labeled cells without affecting the proportion of BrdU-positive neurons and glial cells. FZS also increased the number of BrdU-positive cells in the subventricular zone (SVZ) of the lateral ventricles of 8-month-old SAMP-8 mice. These studies suggest that FZS upregulates neurogenesis by increasing proliferation of neural progenitor cells and prolonging survival of the newborn cells in the hippocampal DG. FZS may be beneficial for the treatment of senile dementia, especially Alzheimer's disease.


Assuntos
Envelhecimento/patologia , Doença de Alzheimer/patologia , Medicamentos de Ervas Chinesas/farmacologia , Hipocampo/patologia , Células-Tronco Neurais/efeitos dos fármacos , Nootrópicos/farmacologia , Envelhecimento/efeitos dos fármacos , Doença de Alzheimer/tratamento farmacológico , Animais , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Imuno-Histoquímica , Aprendizagem em Labirinto , Camundongos , Camundongos Endogâmicos , Fitoterapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...